
The maker of Ozempic and Wegovy has revealed plans to shed around 9,000 jobs globally as the company faces a fiercely competitive market for obesity drugs.
Novo Nordisk’s plans would result in around 11% of the pharmaceutical giant’s 78,400-strong workforce being axed.